Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke

Archives of Neurology

Volumn 65, Issue 9, 2008, Pages 1174-1178

  Martin Schild, Sheryl ^a,d   Hallevi, Hen ^a   Albright, Karen C ^b   Khaja, Aslam M ^c   Barreto, Andrew D ^a   Gonzales, Nicole R ^a   Grotta, James C ^a   Savitz, Sean I ^a,e  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; LABETALOL; NICARDIPINE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; EMERGENCY WARD; FEMALE; GLUCOSE BLOOD LEVEL; HEMORRHAGIC TRANSFORMATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN ISCHEMIA; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 51649129354     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.9.1174     Document Type: Article

References (17)

1. Kleindorfer D, Kissela B, Schneider A, et al; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study [published online ahead of print January 22, 2004]. Stroke. 2004; 35(2):e27-e29. doi:10.1161/01.STR.0000109767.11426. 17. Accessed August 1, 2006.
2. Adams HP Jr, Adams RJ, Brott T, et al; Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34(4):1056-1083.
3. O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Ingall TJ, Louis TA. Report of the t-PA Review Committee. http://Ninds.nih.gov/funding/ review_committees/t-pa_review_committee/t-pa_committee_report.pdf 2004. Accessed September 21, 2007.
4. Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29(8):1504-1509.
5. Aylward PE, Wilcox RG, Horgan JH, et al; GUSTO-I Investigators. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction: a randomized trial. Ann Intern Med. 1996;125(11):891-900.
6. Gurwitz JH, Gore JM, Goldberg RJ, et al; Participants in the National Registry of Myocardial Infarction 2. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 1998;129(8):597-604.
7. Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438-441.
8. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679-1685.
9. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145-1150.
10. Demchuk AM, Tanne D, Hill MD, et al; Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57(3):474-480.
11. Leigh R, Zaidat OO, Suri MF, et al. Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke. 2004;35(8):1903-1907.
12. Tsivgoulis G, Saqqur M, Sharma VK, Lao AY, Hill MD, Alexandrov AV; CLOTBUST Investigators. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke. 2007;38(3):961-966.
13. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35(2):520-526.
14. Oliveira-Filho J, Silva SC, Trabuco CC, Pedreira BB, Sousa EU, Bacellar A. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology. 2003;61(8):1047-1051.
15. Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council; Peripheral Vascular Disease Working Group; Quality of Care Outcomes in Research Interdisciplinary Working Group. Guidelines for the early management of adults with ischemic stroke. The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists [published correction appears in Circulation. 2007;116(18):e515]. Circulation. 2007;115(20):e478- e534. doi:10.1161/CIRCULATIONAHA.107.181486. http://circ.ahajournals.org/cgi. content/full/115/20/e478. Accessed May 25, 2007.
16. Uchino K, Pary J, Grotta JC. Acute Stroke Care: A Manual From the University of Texas-Houston Stroke Team. New York, NY: Cambridge University Press; 2007.
17. Saver JL. Time is brain-quantified. Stroke. 2006;37(1):263-266.